
## James A Lopez Bernal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3018502/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine, 2021, 385, 585-594.	27.0	2,411
2	Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England Journal of Medicine, 2022, 386, 1532-1546.	27.0	1,709
3	Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet, The, 2022, 399, 1303-1312.	13.7	889
4	Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ, The, 2021, 373, n1088.	6.0	881
5	Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Eurosurveillance, 2020, 25, .	7.0	730
6	Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infectious Diseases, The, 2022, 22, 35-42.	9.1	612
7	Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. New England Journal of Medicine, 2022, 386, 340-350.	27.0	501
8	Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infectious Diseases, The, 2020, 20, 1034-1042.	9.1	493
9	Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nature Medicine, 2022, 28, 831-837.	30.7	284
10	SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England. Lancet Infectious Diseases, The, 2021, 21, 344-353.	9.1	272
11	The effect of the late 2000s financial crisis on suicides in Spain: an interrupted time-series analysis. European Journal of Public Health, 2013, 23, 732-736.	0.3	186
12	COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England. Lancet Infectious Diseases, The, 2022, 22, 931-933.	9.1	133
13	A methodological framework for model selection in interrupted time series studies. Journal of Clinical Epidemiology, 2018, 103, 82-91.	5.0	132
14	Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design. International Journal of Epidemiology, 2021, 50, 1124-1133.	1.9	124
15	Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. Journal of Infection, 2022, 84, 675-683.	3.3	87
16	Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nature Communications, 2021, 12, 7217.	12.8	80
17	Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England. JMIR Public Health and Surveillance, 2020, 6, e18606.	2.6	66
18	Excess mortality in the first COVID pandemic peak: cross-sectional analyses of the impact of age, sex, ethnicity, household size, and long-term conditions in people of known SARS-CoV-2 status in England. British Journal of General Practice, 2020, 70, e890-e898.	1.4	51

JAMES A LOPEZ BERNAL

#	Article	IF	CITATIONS
19	The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial Platforms. JMIR Public Health and Surveillance, 2020, 6, e19773.	2.6	44
20	Difference in difference, controlled interrupted time series and synthetic controls. International Journal of Epidemiology, 2019, 48, 2062-2063.	1.9	42
21	All-cause excess mortality observed by age group and regions in the first wave of the COVID-19 pandemic in England. Eurosurveillance, 2020, 25, .	7.0	42
22	An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021. Eurosurveillance, 2021, 26, .	7.0	40
23	Transmission of SARS-CoV-2 in the household setting: A prospective cohort study in children and adults in England. Journal of Infection, 2021, 83, 483-489.	3.3	37
24	Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021. JMIR Public Health and Surveillance, 2021, 7, e24341.	2.6	22
25	Association between the 2012 Health and Social Care Act and specialist visits and hospitalisations in England: A controlled interrupted time series analysis. PLoS Medicine, 2017, 14, e1002427.	8.4	22
26	Lower respiratory tract infection in the first year of life is associated with worse lung function in adult life: prospective results from the Barry Caerphilly Growth study. Annals of Epidemiology, 2013, 23, 422-427.	1.9	21
27	The Use of Quasi-experimental Designs for Vaccine Evaluation. Clinical Infectious Diseases, 2019, 68, 1769-1776.	5.8	20
28	Characteristics associated with COVID-19 vaccine uptake among adults aged 50 years and above in England (8 December 2020–17 May 2021): a population-level observational study. BMJ Open, 2022, 12, e055278.	1.9	18
29	Why did life expectancy in Central and Eastern Europe suddenly improve in the 1990s? An analysis by cause of death. Scandinavian Journal of Public Health, 2015, 43, 796-801.	2.3	16
30	Transmission dynamics of COVID-19 in household and community settings in the United Kingdom, January to March 2020. Eurosurveillance, 2022, 27, .	7.0	16
31	The impact of social and physical distancing measures on COVID-19 activity in England: findings from a multi-tiered surveillance system. Eurosurveillance, 2021, 26, .	7.0	10
32	Rapid community point-of-care testing for COVID-19 (RAPTOR-C19): protocol for a platform diagnostic study. Diagnostic and Prognostic Research, 2021, 5, 4.	1.8	7
33	Hospitalization and Mortality Risk for COVID-19 Cases With SARS-CoV-2 AY.4.2 (VUI-21OCT-01) Compared to Non-AY.4.2 Delta Variant Sublineages. Journal of Infectious Diseases, 2022, 226, 808-811.	4.0	7
34	Mastering Public Health. , 0, , .		6
35	Effectiveness of BNT162b2 COVID-19 booster vaccine against covid-19 related symptoms and hospitalization in England. Nature Medicine, 0, , .	30.7	6
36	Association of Age, Gender, Deprivation, Urbanicity, Ethnicity, and Smoking with a Positive Test for COVID-19 in an English Primary Care Surveillance Network: Cross Sectional Study of the First 500 Cases. SSRN Electronic Journal, 0, , .	0.4	2

#	Article	IF	CITATIONS
37	Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study. JMIR Public Health and Surveillance, 2022, 8, e25803.	2.6	1
38	Proposals to increase the motorway speed limit by 10 mph. BMJ: British Medical Journal, 2011, 344, d7790-d7790.	2.3	0